CHI PHÍ - HIỆU QUẢ CỦA CÁC LIỆU PHÁP NỘI TIẾT TRONG ĐIỀU TRỊ UNG THƯ VÚ: NGHIÊN CỨU TỔNG QUAN HỆ THỐNG

Abstract

Background: Hormone therapy is a novel method of treating breast cancer by slowing or stopping the growth of hormone-sensitive tumors by blocking the body's ability to produce hormones or blocking hormone effects. Objective: This study aimed to systematically review studies that evaluate the cost-effectiveness of hormone therapy, in order to provide evidence-based information to policymakers in choosing breast cancer treatments. Method: Pubmed, SpringerLink, HINARI, and ProQuest databases were searched comprehensively for this systematic review. This study collected and summarized CEA findings and economic evaluation components published during the period of 2015-2022. Results: Of the 21 selected studies, 11 (52.5%) examined hormone therapy combined with other drugs, while 10 appraised hormone therapy alone. In 52.5% of the studies, the population was postmenopausal women with HR+/HER2 metastatic or advanced breast cancer. Most studies were conducted in the US and Europe, from healthcare provider perspectives (38.2%). In most studies, hormone therapy alone was shown to be cost-effective, while combined hormone therapy was found to be not cost-effective when compared to their respective comparators. Conclusion: Breast cancer treatment with these hormone therapies is generally more expensive and can be a huge financial burden for not only patients but also society. Financial aid is necessary to enlarge access and affordability for breast cancer patients.